Reata Pharmaceuticals Announces Stock Halted Amid FDA Cardiovascular And Renal Drugs Advisory Committee Meeting To Review NDA For Bardoxolone Methyl For The Treatment Of Patients With Chronic Kidney Disease Caused By Alport Syndrome